Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians

Similar documents
Recreational Drugs and HIV Antivirals A Guide to Interactions for Clinicians Fall 2002

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV medications HIV medication and schedule plan

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

HIV Drugs and the HIV Lifecycle

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Antiretroviral Dosing in Renal Impairment

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

Antiretrovial Crushable/Liquid Formulation Chart


MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Nobel /03/28. HIV virus and infected CD4+ T cells

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

ANTIRETROVIRAL TREATMENTS (Part 1of

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

COMPLEX MENTAL HEALTH AND SUBSTANCE ABUSE. Veeral Gandhi, BSc. Phm RPh

Drug Treatment Program Update

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

October 26-28: Training Day 1

The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

HIV Management Update 2015

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

Addressing Pediatric Needs of the Most Neglected: next steps

NON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days

Nothing to disclose.

104 MMWR December 17, 2004

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

Quick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents

Medication Errors Focus on the HIV-Infected Patient

Human Immunodeficiency Virus Infection A Modern Day Epidemic

Continuing Education for Pharmacy Technicians

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

HIV Infection & AIDS in Low- and Middle-Income Countries

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.

HIV/AIDS Update 2007

FLORIDA!A MEDICAID' Better Health Care for all Floridians. May

P.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS

Approach for the Newly Diagnosed HIV Positive Patient

Simplifying HIV Treatment Now and in the Future

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

Antiretroviral Pregnancy Registry

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

Appropriate Use & Safety Edits

MEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP

Blood-Borne Pathogens and Post-Exposure Prophylaxis

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting

Overview of HIV. LTC Paige Waterman

Industry Data Request

The Hospitalized HIV+ Patient

Pharmacological considerations on the use of ARVs in pregnancy

The ART of Managing Drug-Drug Interactions in Patients with HIV

Recommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml

Section 6: Treatment of Hepatitis C virus (HCV)

Friday afternoon Programme

New Frontiers for Treatment Strategies for HIV Care

Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos

HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV

continuing education for pharmacists

SUMMARY OF PRODUCT CHARACTERISTICS

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.

STATEMENT OF DISCLOSURE

The New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

TB/HIV Co-Infection. Tuberculosis and HIV

Human Immunodeficiency Virus (HIV)

Comprehensive Guideline Summary

An Update on HIV Therapy Protease Inhibitors for Treatment Experienced Patients

30 Years of HIV: An Update on Treatment Guidelines and Beyond

World AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary

Drug Interactions. Together, we can change the course of the HIV epidemic one woman at a time.

Understanding Viruses CHAPTER 38. Antiviral Agents. Understanding Viruses (cont'd) Viral Infections (cont'd) Viral Infections.

Genotyping and Drug Resistance in Clinical Practice. Case Studies

NATAPNATIONAL. HIV 102: Care & Treatment AIDS TREATMENT ADVOCACY PROJECT. Origins of HIV. Table of Contents. National AIDS Treatment Advocacy Project

Matters of the HAART: An Update on Current Treatment Options for HIV

Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants

what's with it? GOT TO DO [Pharmacokinetics] [Pharmacokinetics] Non-Nukes and PIs: Do They Play Well Together? / Top 3 Websites Winter 2005

Exploring HIV in 2017: What a pharmacist needs to know

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

Transcription:

Recreational Drugs and HIV Antiretrovirals A Guide to Interactions for Clinicians 2009

Recreational Drugs and HIV Antiretrovirals A Guide to Interactions for Clinicians Prepared by: Antonio Urbina, MD, John Faragon, PharmD, BCPS, AAHIVE, Christine Kubin, PharmD and Audrey Castillo, MPH. This clinical support tool is sponsored by the New York/New Jersey AIDS Education Training Center (NY/NJ AETC).The NY/NJ AETC is funded by the Health Resources and Services Administration (HRSA) and is part of the National AIDS Education Training Center Program, a network of federally funded regional and national centers that conduct targeted multidisciplinary HIV/AIDS education and training programs for health care providers. Disclaimer: Neither the AIDS Education and Training Centers nor HRSA condone or recommend the use of illicit drugs in any context. The data in this guide are intended for use by clinicians and other health care providers to provide advice that may reduce harm to patients who use these substances in conjunction with antiretroviral agents. The data in this guide are a compilation of information obtained from published and anecdotal studies through November 2009. PLEASE REFER TO PAGE 10 OF THIS GUIDE FOR IMPORTANT HARM REDUCTION THAT SHOULD BE SHARED WITH PATIENTS. 2 NY/NJ AIDS Education and Training Center Columbia University College of Physicians and Surgeons 100 Haven Avenue, Suite 31G New York, NY 10032 212-304-5530 www.nynjaetc.org nynjaetc@columbia.edu

ALCOHOL Confusion, disorientation, incoordination, loss of GENERAL balance and judgement, respiratory depression, stupor, coma PHARMACOKINETICS Metabolized by alcohol dehydrogenase and aldehyde dehydrogenase; alcohol may induce CYP2E1 and CYP3A N delavirdine (Rescriptor) No known interactions specific to nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) Increases abacavir AUC ~40% (decreased abacavir metabolism by alcohol dehydrogenase) didanosine (ddl, Videx) Increased risk of pancreatitis emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) SEE INDIVIDUAL COMPONENTS tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Protease Inhibitors amprenavir (Agenerase) No known interactions specific to. fosamprenavir (Lexiva) Caution with amprenavir and fosamprenavir oral solution atazanavir (Reyataz) as increased risk of propylene glycol toxicity possible. darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) No known interactions specific to Raltegravir (Isentress) No known interactions specific to AMPHETAMINES (Crystal) Paranoia, anxiety, depression, hallucinations, tachycardia, hypertension, stroke, myocardial infarction, hyperthermia, rhabdomyolysis, diarrhea, erectile dysfunction, teeth grinding Metabolized by hydroxylation and deamination via CYP2D6 pathway; CYP2D6 inhibitors may increase amphetamine levels (try to avoid) N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) Raltegravir (Isentress) No known interactions specific to SEE INDIVIDUAL COMPONENTS Use of full dose ritonavir or low dose ritonavir for boosting other protease inhibitors has the potential to increase amphetamine levels in the blood. No known interactions specific to this combination. Refer to comments for this drug class in general Increases amphetamine blood levels 2-3 times No known interactions specific to No known interactions specific to 3

GENERAL PHARMACOKINETICS N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) 4 Raltegravir (Isentress) AMYL NITRITE (amyl nitrate, poppers) Reduces glutathioine levels; inhaling the fumes acts as a vasodilator (hypotension, tachycardia, headaches), skin flushing No known interactions specific to this combination SEE INDIVIDUAL COMPONENTS No known interactions No known interactions specific to No known interactions specific to BENZODIAZEPINES CNS depression, drowsiness, memory loss, impaired coordination Most agents extensively metabolized in the liver by the CYP3A4 system; lorazepam, oxazepam, and temazepam metabolized by conjugation via glucuronidation. N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) Raltegravir (Isentress) Likely inhibits benzodiazepine metabolism through CYP3A4 inhibition and increases risk of adverse effects; concomitant use should be avoided No known interactions specific to this combination Diazepam drug levels may be increased by etravirine; a decrease in diazepam dosage may be needed SEE INDIVIDUAL COMPONENTS Likely to interfere with metabolism and increase AUC of benzodiazepines; use of PIs with benzodiazepines should be avoided due to increased risk of sedation and respiratory depression; midazolam and triazolam specifically contraindicated with all PIs. DHHS guidelines recommend that parenteral midazolam can be used with caution as a single dose if given in a monitored situation for procedural sedation. No known interactions specific to this combination. Refer to comments for this drug class in general Decreases therapeutic effect of lorazepam, oxazepam, and temazepam (monitor for withdrawal) No known interactions specific to No known interactions specific to

GENERAL PHARMACOKINETICS Mainly metabolized by nonspecific tissue and plasma esterases; some cocaine metabolism ( 10%) via CYP3A4 N delavirdine (Rescriptor) nevirapine (Viramune) No known interactions specific to etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) No known interactions Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) Raltegravir (Isentress) COCAINE (coke, blow) Increases rate of HIV viral replication in vitro, hypertension, cardiac dysrhythmias, myocardial infarction, seizures, depression, anxiety SEE INDIVIDUAL COMPONENTS No known interactions specific to No known interactions specific to ECSTASY (X, MDMA) Tachycardia, hypertension, hyperthermia, dehydration, dry mouth, tense jaw, teeth grinding, depression CYP2D6 demethylation important in metabolism; 2D6 inhibitors are likely to increase ecstasy levels N delavirdine (Rescriptor) nevirapine (Viramune) No known interactions specific to this etravirine (Intelence) combination abacavir (ABC,Ziagen) didanosine (ddl, Videx) SEE INDIVIDUAL COMPONENTS emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) Increase levels of ecstasy zidovudine (AZT, ZDV, Retrovir) No known interactions specific to this Protease Inhibitors combination. Refer to comments for amprenavir (Agenerase) this drug class in general fosamprenavir (Lexiva) Increases risk of kidney stones atazanivir (Reyataz) due to dehydration darunavir (Prezista) Potential to increase ecstasy levels Increases ecstasy levels 5-10 times lopinavir/ritonavir (Kaletra) (AVOID) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) No known interactions specific to Raltegravir (Isentress) No known interactions specific to 5

GENERAL Erectile Dysfunction Agents (sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra)) Hypotension, tachycardia, arrhythmias (cardiac arrest and death), headache, flushing, rhinitis, dyspepsia, nausea, and visual effects (e.g. light sensitivity, changes in color vision), priapism PHARMACOKINETICS Metabolized in the liver via CYP3A4 N delavirdine (Rescriptor) Potential to significantly increase sildenafil, tadalafil, and vardenafil concentrations. Use sildenafil at nevirapine (Viramune) reduced doses of 25 mg every 48 hours, tadalafil at reduced doses of 10 mg every 72 hours, vardenafil etravirine (Intelence) at reduced doses of no more than 2.5 mg every 72 hours and monitor closely for adverse effects. No known interactions specific to. abacavir (ABC,Ziagen) Etravirine has been shown to decrease sildenafil concentrations, though may be used together without didanosine (ddl, Videx) sildenafil dosage adjustment. Sildenafil dosage may need to be adjusted based upon clinical effect. Similar interactions are also predicted with tadalafil and vardenafil. emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) SEE INDIVIDUAL COMPONENTS tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Potential to significantly increase sildenafil, tadalafil, and vardenafil concentrations. Use sildenafil at Protease Inhibitors reduced doses of 25 mg every 48 hours, tadalafil at reduced doses of 10 mg every 72 hours, vardenafil amprenavir (Agenerase) at reduced doses of no more than 2.5 mg every 72 hours and monitor closely for adverse effects. fosamprenavir (Lexiva) No known interactions specific to. Refer to comments for this drug class in general atazanivir (Reyataz) Increases sildenafil AUC ~340% and vardenafil AUC 16-fold. May increase tadalafil concentrations. Refer darunavir (Prezista) to comments for this drug class in general. Monitor closely for adverse effects. Increases sildenafil AUC 1000%, tadalafil AUC 124%, and vardenafil AUC 49-fold and half-life 5-6 fold. lopinavir/ritonavir (Kaletra) Refer to comments for this drug class in general. Monitor closely for adverse effects. nelfinavir (Viracept) Increases sildenafil AUC ~210%. May increase tadalafil and vardenafil concentrations. Refer to comments for this drug class in general. Monitor closely for adverse effects. saquinavir (Fortovase, Invirase) No known interactions specific to Maraviroc (Selzentry) No known interactions specific to Raltegravir (Isentress) 6

GHB (gamma-hydroxy-butyrate, grievous bodily harm, liquid X) Seizures, bradycardia, severe respiratory GENERAL depression, hypotension, vomiting coma, death PHARMACOKINETICS Utilizes CYP2D6 pathway for metabolism N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) Raltegravir (Isentress) No known interactions specific to SEE INDIVIDUAL COMPONENTS PIs potentially increase drug levels of GHB No known interactions specific to. Refer to comments for this drug class in general No known interactions specific to No known interactions specific to HEROIN (smack, brown junk, China White) Dreamlike state of warmth and well-being with small doses; CNS depression, drowsiness, respiratory depression, constricted pupils, nausea/vomiting with excessive doses Utilizes CYP3A4 pathway for metabolism N delavirdine (Rescriptor) nevirapine (Viramune) No known interactions specific to etravirine (Intelence) abacavir (ABC,Ziagen) SEE INDIVIDUAL COMPONENTS didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Possible decrease in heroin levels Protease Inhibitors amprenavir (Agenerase) No known interactions specific to fosamprenavir (Lexiva). Refer to atazanivir (Reyataz) comments for this drug class in darunavir (Prezista) general lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) Reduces heroin levels by 50% saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) No known interactions specific to Raltegravir (Isentress) No known interactions specific to 7

KETAMINE (K, Special K) Paranoia, anxiety, mania, hallucinations, "K-hole" (semi-catatonic stupor). GENERAL Elevated levels may cause tachycardia, hypertension, respiratory depression PHARMACOKINETICS Undergoes N-demethylation and hydroxylation (possibly mediated by CYP3A4); possible weak inhibitor of CPY2D1 and CYP3A4 N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) No known interactions specific to didanosine (ddl, Videx) SEE INDIVIDUAL COMPONENTS emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Likely increase the effect of ketamine Protease Inhibitors (more sedation, increased heart rate and blood amprenavir (Agenerase) pressure). Effects last longer fosamprenavir (Lexiva) No known interactions specific to. atazanivir (Reyataz) Refer to comments for this drug class in general darunavir (Prezista) lopinavir/ritonavir (Kaletra) Combination may increase risk of drug induced hepatitis nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) No known interactions specific to 8 Raltegravir (Isentress) No known interactions specific to LSD (acid) Paranoia, visual and auditory hallucinations N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) No known interactions Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) Raltegravir (Isentress) No known interactions specific to this combination SEE INDIVIDUAL COMPONENTS No known interactions specific to No known interactions specific to

MARIJUANA (Tetrahydrocannabinol;THC) Tachycardia, loss of inhibitions, dry mouth, GENERAL visual hallucinations PHARMACOKINETICS Metabolized in the liver to active metabolite (11-hydroxy THC) via CYP3A4, 2C9, and 2C6; inhibitors/inducers of CYP3A4 may interfere with THC metabolism N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) No known interactions specific to abacavir (ABC,Ziagen) didanosine (ddl, Videx) SEE INDIVIDUAL COMPONENTS emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) P otential to increase THC levels Protease Inhibitors amprenavir (Agenerase) No known interactions specific to. fosamprenavir (Lexiva) Refer to comments for this drug class in general atazanivir (Reyataz) In one study, concentrations of atazanavir darunavir (Prezista) were reduced up to 60% in patients using marijuana. Study did not differentiate lopinavir/ritonavir (Kaletra) whether atazanavir was boosted with nelfinavir (Viracept) ritonavir or not. saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) No known interactions specific to Raltegravir (Isentress) No known interactions specific to METHADONE Generalized CNS depression Primarily utilizes CYP3A4 pathway for metabolism; inhibitor of CYP2D6 and CYP3A4 N delavirdine (Rescriptor) No known interactions specific to this combination nevirapine (Viramune) etravirine (Intelence) Decreases methadone AUC significantly (~60%); titrate methadone dose to effect Decreases methadone AUC significantly abacavir (ABC,Ziagen) (~40-50%); titrate methadone dose to effect Etravirine and methadone may be used together without dosage adjustments; didanosine (ddl, Videx) monitor as needed emtricitabine (FTC, Emtriva) Increases methadone clearance ~22% (an increase in methadone dose may be required in some patients) lamivudine (3TC, Epivir) Decreases didanosine AUC ~41-60% (consider didanosine tablet form dose tenofovir (TDF,Viread) increase or switch to enteric-coated formulation which may not be affected to the same degree ) zidovudine (AZT, ZDV, Retrovir) Decreases stavudine AUC~23% Increases zidovudine AUC ~40% (increases Protease Inhibitors AUC ~29% during chronic treatment) amprenavir (Agenerase) Interaction highly variable and patients fosamprenavir (Lexiva) should be evaluated on an individual basis atazanivir (Reyataz) Decreases methadone levels ~13-30%; monitor for withdrawal and consider darunavir (Prezista) methadone dose increase if needed Decreases methadone AUC ~16-36% (may lopinavir/ritonavir (Kaletra) require methadone dose increase) nelfinavir (Viracept) Decreases methadone AUC ~26-53% (may require methadone dose increase) saquinavir (Fortovase, Invirase) Decreases methadone AUC ~47% (may require methadone dose increase) Decreases methadone AUC ~37% (may require methadone dose increase) Maraviroc (Selzentry) Decrease methadone AUC by ~50% (may require methadone dosage increase) Raltegravir (Isentress) No known interactions specific to 9

PATIENT INFORMATION TO REDUCE HARM ALCOHOL If you take ddi, do not drink alcohol. Try to avoid alcohol or use modestly. AMYL NITRITE (amyl nitrate, poppers) Do not use with sildenafil (Viagra), vardenafil (Levitra) or tadalafil (Cialis). Heart problems, glaucoma, or anemia make poppers more dangerous. COCAINE (coke, blow) Don t get so high you forget to stick to your antiretroviral regimen. Avoid cocaine if you have heart or liver problems, or high blood pressure Erectile Dysfunction Agents Do not mix with amyl or butyl nitrates (poppers). Combination can cause sudden drop in blood pressure leading to fainting or heart attack. GHB Start with half-teaspoon, wait half-hour before taking more. Do not mix with alcohol, tranquilizers, pain-killers, or allergy medications. Do not use if you are alone. The dose you used last week can kill you this week. KETAMINE (K, Special K) Start with 1/3 or 1/2 of usual dose. Wait a half-hour before doing more. Always use with a friend, never alone. AMPHETAMINES (Crystal) Avoid use if you have heart or liver problems, or high blood pressure. Recent reports of transmitted HIV resistance in patients using methamphetamine and practicing unsafe sex. BENZODIAZEPINES Any changes to your methadone regimen or HIV medications should be reported to both providers to ensure potential interactions are identified. ECSTASY (X, MDMA) Start with 1/4 or 1/2 tablet. Drink plenty of water. HEROIN (smack, brown junk, China, White) Start with normal dose and increase only if you experience less of a hit and less buzz. Safe injecting. Do not mix with other recreational drugs. METHADONE Any changes to your methadone regimen or HIV medications should be reported to both providers to ensure potential interactions are identified. 10

RESOURCES The National AETC Program also includes the following services: National HIV/AIDS Clinicians Consultation Center: 1-800-933-3413 Offering treating clinicians current HIV clinical and drug information and individualized, expert case consultation. Post-Exposure Prophylaxis 24 hour hotline: 1-888-HIV-4911 Providing consulation for occupational exposures. Perinatal Hotline: 1-888-448-8765 Providing consulation for perinatal exposure and treatment. AETC HIV/AIDS National Resource Center: http://www.aidsetc.org/ Providing resources (including curricula and lecture slide sets) on HIV disease treatment, education and data. 11

FOR FURTHER INFORMATION, PLEASE VISIT ONE OF THE FOLLOWING WEBSITES: NY/NJ AIDS Education and Training Center www.nynjaetc.org U.S. DHHS AIDS Info aidsinfo.nih.gov NYSDOH AIDS Institute Clinical Resources www.hivguidelines.org Substance Abuse and Mental Health Services Administration www.samhsa.gov Addiction Technology Transfer Center www.nattc.org Harm Reduction Coalition www.harmreduction.org 12